Efficacy and safety of Tocilizumab in the treatment of Rheumatoid Arthritis: An umbrella review

Silva, David; Moreira, Fernando; Santos, Marlene

http://hdl.handle.net/10400.22/30628

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
COM_Fernando Moreira.pdf		142.23 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Tocilizumab (TCZ) is a humanized immunoglobulin G1 monoclonal antibody that targets and inhibits the interleukin-6 (IL-6) receptor. As a selective inhibitor of this cytokine, TCZ offers a targeted approach in managing inflammatory conditions. Given its specificity and potential therapeutic benefits, this article aims to provide a comprehensive summary of the efficacy and safety of TCZ in the treatment of RA.

Keywords

Immune system Tumor immunology Autoimmune disease

URI

http://hdl.handle.net/10400.22/30628

Citation

Silva, D., Moreira, F., & Santos, M. (2025). Efficacy and safety of Tocilizumab in the treatment of Rheumatoid Arthritis: An umbrella review. 34 (1), 10, 11. https://www.mdpi.com/2673-9992/34/1/1